Detalles de la búsqueda
1.
Computational approaches to therapeutic antibody design: established methods and emerging trends.
Brief Bioinform
; 21(5): 1549-1567, 2020 09 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31626279
2.
Validation of ion mobility spectrometry - mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase.
Rapid Commun Mass Spectrom
; : e9130, 2021 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34038603
3.
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
J Med Chem
; 49(22): 6465-88, 2006 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-17064066
4.
Crystal structure of inositol 1-phosphate synthase from Mycobacterium tuberculosis, a key enzyme in phosphatidylinositol synthesis.
Structure
; 10(3): 393-402, 2002 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12005437
5.
Crystal structure of human thymidine phosphorylase in complex with a small molecule inhibitor.
Structure
; 12(1): 75-84, 2004 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-14725767
6.
Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat.
ACS Med Chem Lett
; 7(1): 94-9, 2016 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26819673
7.
Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.
Oncotarget
; 7(17): 24252-68, 2016 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-26992226
8.
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Cancer Res
; 76(11): 3307-18, 2016 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27020862
9.
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase.
Nat Commun
; 6: 7877, 2015 Jul 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-26203596
10.
Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.
J Med Chem
; 58(8): 3522-33, 2015 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-25790336
11.
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
J Med Chem
; 58(20): 8128-40, 2015 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26407012
12.
FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures.
ACS Med Chem Lett
; 5(2): 166-71, 2014 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900792
13.
Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
Structure
; 22(12): 1764-1774, 2014 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-25465127
14.
Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα.
Biosci Rep
; 33(4)2013 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-23863106
15.
Structural approaches to obtain kinase selectivity.
Trends Pharmacol Sci
; 33(5): 273-8, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22503441
16.
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.
J Med Chem
; 55(11): 5003-12, 2012 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22612866
17.
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
J Med Chem
; 55(7): 3285-306, 2012 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-22417091
18.
Correction to Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators.
J Med Chem
; 59(7): 3576, 2016 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27003331
19.
Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
J Med Chem
; 52(23): 7901-5, 2009 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-19736928
20.
Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase.
Biochemistry
; 44(50): 16475-90, 2005 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16342939